RORC and neoplasm: At the end of the study, when spleens and tumors were examined, the number of transferred Thy1.1+ T cells was significantly higher in mice receiving RORγ-agonist-treated Tc17 cells compared with mice receiving vehicle-treated Tc17 cells (Fig. 4D and Fig. S4) despite equal numbers of cells being transferred, suggesting that the RORγ-agonist-treated cells survive and/or proliferate better than untreated cells after being transferred into tumor-bearing mice.